Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735140 | 0.90 | KDM4E (0.43) | KDM4EMEN1KMT2AALDH1A1HIF1A | |
| SCHEMBL2735142 | 0.89 | KDM4E (0.52) | KDM4EKMT2ACCNE2CCNE1CDK2 | |
| SCHEMBL2735151 | 0.86 | KDM4E (0.53) | KDM4EMEN1KMT2ARXFP1ALDH1A1 | |
| SCHEMBL2735248 | 0.86 | RAPGEF4 (0.41) | KDM4EMEN1KMT2AALDH1A1PDE9A | |
| SCHEMBL2735145 | 0.85 | KDM4E (0.52) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2735169 | 0.84 | PDE9A (0.45) | KDM4EMEN1KMT2AALDH1A1HIF1A | |
| SCHEMBL2735214 | 0.83 | ALDH1A1 (0.40) | KDM4EMEN1KMT2AALDH1A1HIF1A | |
| SCHEMBL2735144 | 0.83 | KDM4E (0.49) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL212270 | 0.82 | PNP (0.38) | KDM4EMEN1KMT2AALDH1A1MAPK8 | |
| SCHEMBL2735149 | 0.82 | KDM4E (0.48) | KDM4EMEN1KMT2AALDH1A1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2006125554-A1 | USE OF CYANOPYRIMIDINES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255118-A1 | Cyanopyrimidinones | CACYBP, CHRM4, CHRNA4 | KDM4E 1288/4885MEN1 2603/4885KMT2A 3830/4885 |
| US-20110207735-A1 | CYANOPYRIMIDINONES | CACYBP, CHRM4, CHRNA4 | KDM4E 1288/4885MEN1 2603/4885KMT2A 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.